X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB PANACEA BIOTECH UNICHEM LAB/
PANACEA BIOTECH
 
P/E (TTM) x 30.2 174.0 17.3% View Chart
P/BV x 3.2 3.9 82.2% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 UNICHEM LAB   PANACEA BIOTECH
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
PANACEA BIOTECH
Mar-14
UNICHEM LAB/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs334149 224.6%   
Low Rs17482 211.4%   
Sales per share (Unadj.) Rs146.984.1 174.6%  
Earnings per share (Unadj.) Rs11.9-18.3 -65.0%  
Cash flow per share (Unadj.) Rs16.2-6.7 -241.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs105.183.7 125.6%  
Shares outstanding (eoy) m90.8461.25 148.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.71.4 126.0%   
Avg P/E ratio x21.4-6.3 -338.5%  
P/CF ratio (eoy) x15.7-17.2 -91.0%  
Price / Book Value ratio x2.41.4 175.1%  
Dividend payout %16.80-   
Avg Mkt Cap Rs m23,0737,074 326.2%   
No. of employees `0005.72.8 206.3%   
Total wages/salary Rs m2,5581,449 176.5%   
Avg. sales/employee Rs Th2,352.51,874.1 125.5%   
Avg. wages/employee Rs Th450.9527.0 85.6%   
Avg. net profit/employee Rs Th190.4-407.7 -46.7%   
INCOME DATA
Net Sales Rs m13,3465,154 259.0%  
Other income Rs m192100 192.3%   
Total revenues Rs m13,5385,254 257.7%   
Gross profit Rs m1,639-766 -213.9%  
Depreciation Rs m390711 54.9%   
Interest Rs m291,503 1.9%   
Profit before tax Rs m1,412-2,881 -49.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-4-6 64.9%   
Extraordinary Inc (Exp) Rs m-351,771 -2.0%   
Tax Rs m29317 1,742.3%   
Profit after tax Rs m1,080-1,121 -96.4%  
Gross profit margin %12.3-14.9 -82.6%  
Effective tax rate %20.7-0.6 -3,554.0%   
Net profit margin %8.1-21.8 -37.2%  
BALANCE SHEET DATA
Current assets Rs m5,9793,810 156.9%   
Current liabilities Rs m2,4328,365 29.1%   
Net working cap to sales %26.6-88.4 -30.1%  
Current ratio x2.50.5 539.8%  
Inventory Days Days63156 40.5%  
Debtors Days Days6067 89.8%  
Net fixed assets Rs m6,40314,480 44.2%   
Share capital Rs m18261 296.4%   
"Free" reserves Rs m9,293903 1,029.0%   
Net worth Rs m9,5485,127 186.2%   
Long term debt Rs m2305,832 4.0%   
Total assets Rs m12,84319,433 66.1%  
Interest coverage x50.0-0.9 -5,458.9%   
Debt to equity ratio x01.1 2.1%  
Sales to assets ratio x1.00.3 391.8%   
Return on assets %8.62.0 439.7%  
Return on equity %11.3-21.9 -51.7%  
Return on capital %14.33.6 394.2%  
Exports to sales %29.224.5 119.2%   
Imports to sales %6.310.2 62.3%   
Exports (fob) Rs m3,9001,264 308.6%   
Imports (cif) Rs m847525 161.3%   
Fx inflow Rs m4,3561,539 283.0%   
Fx outflow Rs m1,162942 123.4%   
Net fx Rs m3,194597 534.8%   
CASH FLOW
From Operations Rs m1,119599 186.8%  
From Investments Rs m-853-438 194.9%  
From Financial Activity Rs m-334-303 110.4%  
Net Cashflow Rs m-68-141 48.3%  

Share Holding

Indian Promoters % 50.1 74.5 67.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 0.6 2,516.7%  
FIIs % 3.0 1.3 230.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 23.6 134.3%  
Shareholders   20,176 10,259 196.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare UNICHEM LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 22, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - WOCKHARDT LTD. COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS